These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7469590)

  • 1. [Changes in aldosterone receptors in congestive heart disease. Report of a case].
    Sánchez G; Posadas C; Boyer JL; Guzmán J; Serrano P
    Arch Inst Cardiol Mex; 1980; 50(4):461-9. PubMed ID: 7469590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intolerance to spironolactone in refractory cardiac insufficiency. Probable changes in the aldosterone receptors. Study of 11 cases].
    Sänchez Torres G; Posadas C; Boyer JL; Guzmán Lara J; Serrano P
    Arch Inst Cardiol Mex; 1981; 51(3):233-40. PubMed ID: 6456707
    [No Abstract]   [Full Text] [Related]  

  • 3. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure.
    Tsutamoto T; Wada A; Maeda K; Hayashi M; Tsutsui T; Ohnishi M; Fujii M; Matsumoto T; Yamamoto T; Takayama T; Ishii C
    J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S19-22. PubMed ID: 12688391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutically induced aldosteronism in hydropic cardiac insufficiency].
    Kaufmann W
    Arzneimittelforschung; 1969 May; 19(5):802-3. PubMed ID: 5819794
    [No Abstract]   [Full Text] [Related]  

  • 6. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
    Shah KB; Rao K; Sawyer R; Gottlieb SS
    J Am Coll Cardiol; 2005 Sep; 46(5):845-9. PubMed ID: 16139135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
    Diercks GF; Overdiek JW; van Veldhuisen DJ
    Ned Tijdschr Geneeskd; 2001 Feb; 145(5):204-8. PubMed ID: 11219145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
    Cruz CS; Cruz LS; Domingues GS; Souza CA
    Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Induced aldosteronism in hydropic heart insufficiency].
    Kaufmann W; Steiner B; Dürr F; Meurer KA; Behn C
    Klin Wochenschr; 1969 Jan; 47(1):16-25. PubMed ID: 5381434
    [No Abstract]   [Full Text] [Related]  

  • 13. Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message.
    Witham MD; Gillespie ND; Struthers AD
    Br J Clin Pharmacol; 2004 Nov; 58(5):554-7. PubMed ID: 15521905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs.
    Yang SS; Han W; Zhou HY; Dong G; Wang BC; Huo H; Wei N; Cao Y; Zhou G; Xiu CH; Li WM
    Chin Med J (Engl); 2008 Jan; 121(1):38-42. PubMed ID: 18208664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spironolactone for heart failure.
    Med Lett Drugs Ther; 1999 Sep; 41(1061):81-2. PubMed ID: 10505071
    [No Abstract]   [Full Text] [Related]  

  • 17. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy of captopril and spironolactone for refractory congestive heart failure.
    Han YL; Tong M; Jing QM; Hu XL; Liu JQ
    Chin Med J (Engl); 1994 Sep; 107(9):688-92. PubMed ID: 7805462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neuroendocrine-immune interface gone awry in aldosteronism.
    Weber KT
    Cardiovasc Res; 2004 Dec; 64(3):381-3. PubMed ID: 15537489
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.